What is the role of maintenance therapy in the treatment of non-small cell lung cancer?

Abstract

References

Asukai, Y. , Valladares, A. , Camps, C. , Wood, E. , Taipale, K. , Arellano, J. et al. (2010) Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. BMC Cancer 10: 26.

Azzoli, C.G. , Baker Jr, S. , Temin, S. , Pao, W. , Aliff, T. , Brahmer, J. et al. (2009) American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol 27: 6251-6266.

Belani, C.P. , Lee, J.S. , Socinski, M.A. , Robert, F. , Waterhouse, D. , Rowland, K. et al. (2005) Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer . Ann Oncol 16: 1069-1075.

Brodowicz, T. , Krzakowski, M. , Zwitter, M. , Tzekova, V. , Ramlau, R. , Ghilezan, N. et al. (2006) Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52: 155-163.

Cappuzzo, F.C.T. , Stelmakh, L. , Cicenas, S. , Szczesna, A. , Juhasz, E. and Esteban Gonzalez, E. et al., on behalf of the SATURN Investigators ( 2009) SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 27(Suppl): Abstract 8001.

Carlson, J.J. , Reyes, C. , Oestreicher, N. , Lubeck, D. , Ramsey, S.D. and Veenstra, D.L. ( 2008) Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 61: 405-415.

Ciuleanu, T. , Brodowicz, T. , Zielinski, C. , Kim, J.H. , Krzakowski, M. , Laack, E. et al. (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374: 1432-1440.

Douillard, J.Y. , Shepherd, F.A. , Hirsh, V. , Mok, T. , Socinski, M.A. , Gervais, R. et al. (2010) Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28: 744-752.

Fidias, P.M. , Dakhil, S.R. , Lyss, A.P. , Loesch, D.M. , Waterhouse, D.M. , Bromund, J.L. et al. (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 27: 591-598.

10.

Fojo, T. and Grady, C. (2009) How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 101: 1044-1048.

11.

Fossella, F. , Pereira, J.R. , von Pawel, J. , Pluzanska, A. , Gorbounova, V. , Kaukel, E. et al. (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016-3024.

12.

Hanna, N. , Shepherd, F.A. , Fossella, F.V. , Pereira, J.R. , De Marinis, F. , von Pawel, J. et al. (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy . J Clin Oncol 22: 1589-1597.

13.

Kim, E.S. , Hirsh, V. , Mok, T. , Socinski, M.A. , Gervais, R. , Wu, Y.L. et al. (2008) Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809-1818.

14.

Kobayashi, S. , Boggon, T.J. , Dayaram, T. , Janne, P.A. , Kocher, O. , Meyerson, M. et al. (2005) EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 352: 786-792.

15.

Lyseng-Williamson, K.A. (2010) Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics 28: 75-92.

16.

Martoni, A. , Marino, A. , Sperandi, F. , Giaquinta, S. , Di Fabio, F. , Melotti, B. et al. (2005) Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 41: 81-92.

17.

Miller, V.A.O.C.P. , Soh, C. , Kabbinavar, F. , and for the ATLAS Investigators ( 2009) A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 27: Abstract LBA8002.

18.

Mok, T.S. , Wu, Y.L. , Thongprasert, S. , Yang, C.H. , Chu, D.T. , Saijo, N. et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma . N Engl J Med 361: 947-957.

19.

Non-small Cell Lung Cancer Collaborative Group ( 1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials . BMJ 311: 899-909.

20.

OSI Pharmaceuticals, I.a.G., Inc. (2009) FDA Advisory Committee recommends against approving tarveva for first-line maintenance use in advanced non-small cell lung cancer.

21.

Park, J.O. , Kim, S.W. , Ahn, J.S. , Suh, C. , Lee, J.S. , Jang, J.S. et al. (2007) Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small cell lung cancer. J Clin Oncol 25: 5233-5239.

22.

Pfister, D.G. , Johnson, D.H. , Azzoli, C.G. , Sause, W. , Smith, T.J. , Baker Jr, S. et al. (2004) American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353.

23.

Reck, M. , von Pawel, J. , Zatloukal, P. , Ramlau, R. , Gorbounova, V. , Hirsh, V. et al. (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAil. J Clin Oncol 27: 1227-1234.

24.

Rosell, R. , Moran, T. , Queralt, C. , Porta, R. , Cardenal, F. , Camps, C. et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967.

25.

Rudd, R.M. , Gower, N.H. , Spiro, S.G. , Eisen, T.G. , Harper, P.G. , Littler, J.A. et al. (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small cell lung cancer: a phase III randomized study of the London Lung Cancer Group . J Clin Oncol 23: 142-153.

26.

Sandler, A. , Gray, R. , Perry, M.C. , Brahmer, J. , Schiller, J.H. , Dowlati, A. et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355: 2542-2550.

27.

Scagliotti, G. , Hanna, N. , Fossella, F. , Sugarman, K. , Blatter, J. , Peterson, P. et al. (2009) The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14: 253-263.

28.

Scagliotti, G.V. , De Marinis, F. , Rinaldi, M. , Crino, L. , Gridelli, C. , Ricci, S. et al. (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 20: 4285-4291.

29.

Scagliotti, G.V. , Parikh, P. , von Pawel, J. , Biesma, B. , Vansteenkiste, J. , Manegold, C. et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 26: 3543-3551.

30.

Sederholm, C. , Hillerdal, G. , Lamberg, K. , Kolbeck, K. , Dufmats, M. , Westberg, R. et al. (2005) Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 23: 8380-8388.

31.

Shepherd, F.A. , Rodrigues Pereira, J. , Ciuleanu, T. , Tan, E.H. , Hirsh, V. , Thongprasert, S. et al. (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353: 123-132.

32.

Socinski, M.A. , Schell, M.J. , Peterman, A. , Bakri, K. , Yates, S. , Gitten, R. et al. (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small cell lung cancer. J Clin Oncol 20: 1335-1343.

33.

Soon, Y.Y. , Stockler, M.R. , Askie, L.M. and Boyer, M.J. (2009) Duration of chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 27: 3277-3283.

34.

Tsao, M.S. , Sakurada, A. , Cutz, J.C. , Zhu, C.Q. , Kamel-Reid, S. , Squire, J. et al. (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353: 133-144.

35.

von Plessen, C. , Bergman, B. , Andresen, O. , Bremnes, R.M. , Sundstrom, S. , Gilleryd, M. et al. (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small cell lung cancer. Br J Cancer 95: 966-973.

36.

Westeel, V. , Quoix, E. , Moro-Sibilot, D. , Mercier, M. , Breton, J.L. , Debieuvre, D. et al. (2005) Randomized study of maintenance vinorelbine in responders with advanced non-small cell lung cancer. J Natl Cancer Inst 97: 499-506.